
Join to View Full Profile
1110 Oak StAlyce Elmore Kraemer Cancer Care CenterWest Bend, WI 53095
Phone+1 262-334-8484
Fax+1 414-805-4944
Dr. Kamaraju is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
- University of MinnesotaFellowship, Hematology and Medical Oncology, 1999 - 2002
- Hennepin HealthcareResidency, Internal Medicine, 1996 - 1999
- University of Arizona College of Medicine-Tucson (South Campus)Internship, Internal Medicine, 1995 - 1996
- Guntur Medical College NTRClass of 1993
Certifications & Licensure
- WI State Medical License 2002 - 2025
- TX State Medical License 2008 - 2015
- MN State Medical License 1998 - 2005
- IL State Medical License 2002 - 2002
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer Start of enrollment: 2010 Oct 12
- Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study) Start of enrollment: 2021 Oct 05
- A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer Start of enrollment: 2022 Mar 07
Roles: Principal Investigator, Contact
- Join now to see all
Publications & Presentations
PubMed
- National trends in neoadjuvant systemic therapy utilization in patients with early-stage HER2-positive breast cancer from 2016-2021: The impact of the KATHERINE trial.Lauren N Cohen, Christine C Rogers, Jan Irene C Lloren, Sailaja Kamaraju, Lubna N Chaudhary
Breast Cancer Research and Treatment. 2025-06-03 - Breast Cancer Outcomes in Transgender and Gender-Diverse Patients in the National Cancer Database.Kelley Chan, Joseph H Cotler, Alexandra C Istl, Sailaja Kamaraju, Andrew E Petroll
JAMA Oncology. 2025-05-22 - 1 citationsA Phase II Trial of Onapristone and Fulvestrant for Patients With ER+ and HER2- Metastatic Breast Cancer.Sailaja Kamaraju, Amy M Fowler, Sergey Tarima, Lubna N Chaudhary, Mark E Burkard
Clinical Breast Cancer. 2025-04-01
Press Mentions
- BriaCell Presents Unprecedented Overall Survival Data in Metastatic Breast CancerDecember 11th, 2024
- Context Therapeutics® to Present Clinical Data on ONA-XR in Breast Cancer at 2021 San Antonio Breast Cancer SymposiumNovember 19th, 2021
- Context Therapeutics and Wisconsin Oncology Network (WON) to Evaluate Apristor Combination Therapy for Women with Advanced Breast CancerOctober 7th, 2019
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: